Table 5.
Safety and efficacy of TAF and TDF at 48 weeks
| THF (n = 154) | TAF (n = 46) | Total (n = 200) | p value | |
|---|---|---|---|---|
| ΔCholesterol, mg/dL | –10.00 (–28.00–8.00) | 5.50 (–22.25–30.75) | –8.50 (–26.00–12.00) | 0.010* |
| AALP, IU/L | –5.50 (–4.25–28.00) | –11.00 (–20.00–8.00) | –6.83 (–34.75–19.25) | 0.744 |
| ΔeGFR, mg/dL | –3.35 (–16.13–10.70) | 1.90 (–6.72–8.50) | –0.60 (–12.50–10.38) | 0.071 |
| Complications of LC, n (%) | 1 (0.7) | 0 (0) | 1 (0.7) | 0.584 |
| Varices | 0 (0) | 0 (0) | 0 (0) | |
| Variceal bleeding | 1 (100) | 0 (0) | 1 (100) | |
| Ascites | 0 (0) | 0 (0) | 0 (0) | |
| SBP | 0 (0) | 0 (0) | 0 (0) | |
| HE | 0 (0) | 0 (0) | 0 (0) | |
| HBeAg seroconversion | 12/80 (15.0%) | 3/18 (16.7%) | 15/98 (15.3%) | 0.859 |
| CVR | 127/154 (82.5%) | 35/46 (76.1%) | 162/200 (81.0%) | 0.333 |
| ALT normalization | 117/152 (77.0%) | 36/46 (78.3%) | 153/198 (77.3%) | 0.855 |
TDF, tenofovir disoproxil fumarate; TAF, tenofovir alafenamide; ALP, alkaline phosphatase; eGFR, estimated glomerular filtration rate; LC, liver cirrhosis; SBP, spontaneous bacterial peritonitis; HE, hepatic encephalopathy; CVR, complete viral response; ALT, alanine amino-transferase; HBeAg, hepatitis B e antigen. p < 0.05 is considered statistically significant.